CVS Caremark Deal Restores Lilly's Obesity Drug Coverage, Reshapes Market Access

CVS Caremark, one of the largest pharmacy benefit managers in the United States, has reached a new formulary agreement with Eli Lilly that covers Foundayo, Lilly's oral GLP-1 receptor agonist for obesity, and restores preferred coverage for Zepbound, its injectable tirzepatide product. The deal marks a significant shift in the competitive landscape for obesity medications, ending Novo Nordisk's exclusive preferred status on CVS Caremark's national template formulary.

Pharmacy benefit managers control formulary access for tens of millions of patients across commercial, Medicare, and Medicaid plans. Their decisions about preferred status directly influence which medications prescribers select and which treatments patients can afford. When CVS Caremark excluded Zepbound from its preferred tier in favour of Novo Nordisk's Wegovy, it created a structural commercial advantage that tilted prescribing patterns regardless of clinical data. This new agreement removes that imbalance.

Foundayo Enters the Formulary

Foundayo represents a first-in-class milestone: it is the first oral GLP-1 receptor agonist approved for chronic weight management. Until now, all GLP-1 and GIP/GLP-1 therapies for obesity required parenteral delivery, a barrier that deterred some patients and complicated adherence. An oral option on a major national formulary gives prescribers and patients a new delivery format that may broaden uptake among those reluctant to start injectable therapy.

The deal also restores preferred-tier placement for Zepbound, Lilly's dual GIP/GLP-1 agonist, which had been effectively shut out of one of the largest PBM networks in the country. With both Foundayo and Zepbound now covered alongside Wegovy, the formulary reflects a more competitive market in which clinical differentiation and patient preference can drive prescribing rather than a single PBM rebate structure.

Commercial Implications

Financial terms of the agreement were not disclosed. PBM negotiations typically involve confidential rebates and volume-based incentives, making it difficult to assess the precise concessions Lilly may have offered. What is clear is the strategic significance: obesity drug competition now operates on two fronts-clinical efficacy and commercial access. A molecule that performs well in trials still needs formulary placement to reach patients at scale.

The obesity drug market is expected to exceed $100 billion globally by the end of this decade, and PBM formulary decisions will shape how that value is distributed among manufacturers. For Lilly, regaining access through CVS Caremark removes a bottleneck that had constrained its commercial trajectory relative to Novo Nordisk. For patients, the practical outcome is greater choice: prescribers can now match therapy to individual clinical needs without formulary restrictions acting as a de facto filter.

As more PBM contracts come up for renewal, the CVS Caremark-Lilly agreement may serve as a template for how payers negotiate access in a market with multiple clinically validated obesity therapies. The era of single-product preferred status appears to be ending, replaced by formularies that accommodate a broader range of options.

For educational purposes only. This content is informational and reflects publicly reported research developments. It is not medical advice and makes no therapeutic claims. Products referenced are for research use only. Consult a qualified healthcare professional for any medical question.